HIV patients with belly fat and high liver enzymes who lost at least 8% of their visceral fat from the drug saw their ALT drop by about 9 points (18%) and AST by 4 points (10%) after six months of treatment.

For people with HIV and belly fat who have high liver enzyme levels, those who lost at least 8% of their visceral fat from the drug had much bigger drops in their liver enzyme numbers compared to those who didn't lose much fat, and this difference was statistically significant.

For people with HIV and belly fat who have high liver enzyme levels, those who lost at least 8% of their visceral fat from tesamorelin treatment had much bigger drops in their liver enzyme levels compared to those who didn't lose much fat.

HIV patients with high liver enzymes who lost at least 8% visceral fat after taking tesamorelin saw their ALT drop by about 9 units on average, while those without fat loss had a slight increase, showing a clear benefit from fat reduction.

Even after stopping tesamorelin and some fat coming back, the liver enzyme improvements stayed for a year in patients who initially lost visceral fat.

HIV patients with high liver enzymes who lost at least 8% of their visceral fat from the drug were 2.5 times more likely to have their ALT levels return to normal compared to those who didn't lose much fat.